Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957661 | 0.87 | MRGPRX4 (0.66) | MRGPRX4SLC6A4EGFRERBB2ALDH1A1 | |
| SCHEMBL6979470 | 0.86 | MRGPRX4 (0.57) | MRGPRX4SLC6A4PDCD1CD274HTR6 | |
| SCHEMBL22469778 | 0.83 | MRGPRX4 (0.76) | MRGPRX4SLC6A4PDCD1CD274HTR6 | |
| SCHEMBL31568445 | 0.83 | MRGPRX4 (0.76) | MRGPRX4SLC6A4PDCD1CD274HTR6 | |
| SCHEMBL14548608 | 0.83 | MRGPRX4 (0.51) | MRGPRX4SLC6A4PDCD1CD274HTR6 | |
| SCHEMBL22480554 | 0.83 | MRGPRX4 (1.00) | MRGPRX4SLC6A4ALDH1A1MAPT | |
| SCHEMBL21340514 | 0.81 | FFAR1 (0.56) | MRGPRX4 | |
| SCHEMBL9975338 | 0.81 | ACP1 (0.55) | MRGPRX4EGFRERBB2MAPT | |
| SCHEMBL9975357 | 0.81 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL14854689 | 0.81 | MRGPRX4 (0.76) | MRGPRX4SLC6A4EGFRERBB2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | MRGPRX4 952/4885SLC6A4 1036/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.